| Cited nodes | Nodes / Authors | GCS | LCS |
| 2 | 1 2000 AIDS 14():S125-S127
Heeney JL; Hahn BH
Vaccines and immunology: elucidating immunity to HIV-1 and current prospects for AIDS vaccine development | 2 | 0
|
| 1 | 2 2000 AIDS 14():S141-S151
Bogers WMJM; Cheng-Mayer C; Montelaro RC
Developments in preclinical AIDS vaccine efficacy models | 6 | 1
|
| 1 | 3 2000 AIDS 14():S167-S174
Mascola LR; Frankel SS; Broliden K
HIV-1 entry at the mucosal surface: role of antibodies in protection | 0 | 0
|
| 1 | 4 2000 AIDS RESEARCH AND HUMAN RETROVIRUSES 16(18):2019-2035
Bures R; Gaitan A; Zhu TF; Graziosi C; McGrath KM; Tartaglia J; Caudrelier P; EL Habib R; Klein M; Lazzarin A; Stablein DM; Deers M; Corey L; Greenberg ML; Schwartz DH; Montefiori DC
Immunization with recombinant canarypox vectors expressing membrane-anchored glycoprotein 120 followed by glycoprotein 160 boosting fails to generate antibodies that neutralize R5 primary isolates of human immunodeficiency virus type 1 | 15 | 7
|
| 1 | 5 2000 ANTIVIRAL RESEARCH 47(2):57-77
Sawyer LA
Antibodies for the prevention and treatment of viral diseases | 3 | 0
|
| 1 | 6 2000 CLINICAL IMMUNOLOGY 97(1):59-68
Lu FX
Predominate HIV1-specific IgG activity in various mucosal compartments of HIV1-infected individuals | 0 | 0
|
| 2 | 7 2000 CURRENT OPINION IN IMMUNOLOGY 12(4):425-431
Edelson BT; Unanue ER
Immunity to Listeria infection | 3 | 0
|
| 1 | 8 2000 GENES AND IMMUNITY 1(5):308-315
Stevceva L; Abimiku AG; Franchini G
Targeting the mucosa: genetically engineered vaccines and mucosal immune responses | 6 | 0
|
| 1 | 9 2000 JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION 284(2):215-222
D'Souza MP; Cairns JS; Plaeger SF
Current evidence and future directions for targeting HIV entry - Therapeutic and prophylactic strategies | 20 | 0
|
| 1 | 10 2000 JOURNAL OF IMMUNOLOGY 165(11):6454-6462
Belyakov IM; Ahlers JD; Clements JD; Strober W; Berzofsky JA
Interplay of cytokines and adjuvants in the regulation of mucosal and systemic HIV-specific CTL | 11 | 1
|
| 1 | 11 2000 JOURNAL OF INFECTIOUS DISEASES 182(2):579-589
Nathanson N; Mathieson BJ
Biological considerations in the development of a human immunodeficiency virus vaccine | 11 | 1
|
| 2 | 12 2000 JOURNAL OF VIROLOGY 74(17):7922-7935
Edinger AL; Ahuja M; Sung T; Baxter KC; Haggarty B; Doms RW; Hoxie JA
Characterization and epitope mapping of neutralizing monoclonal antibodies produced by immunization with oligomeric simian immunodeficiency virus envelope protein | 6 | 0
|
| 1 | 13 2000 JOURNAL OF VIROLOGY 74(20):9749-9754
Cho MW; Lee MK; Chen CH; Matthews T; Martin MA
Identification of gp120 regions targeted by a highly potent neutralizing antiserum elicited in a chimpanzee inoculated with a primary human immunodeficiency virus type 1 isolate | 6 | 3
|
| 1 | 14 2000 JOURNAL OF VIROLOGY 74(22):10514-10522
Wang SW; Kozlowski PA; Schmelz G; Manson K; Wyand MS; Glickman R; Montefiori D; Lifson JD; Johnson RP; Neutra MR; Aldovini A
Effective induction of simian immunodeficiency virus-specific systemic and mucosal immune responses in primates by vaccination with proviral DNA producing intact but noninfectious virions | 7 | 3
|
| 1 | 15 2000 MOLECULAR MEDICINE TODAY 6(5):184-184
Dorrell S
Mucosal protection against HIV - a new role for IgG? | 0 | 0
|
| 1 | 16 2000 NATURE BIOTECHNOLOGY 18(10):1038-1039
Whaley KJ; Zeitlin L
Transgenic commensals as mucosal protectants | 1 | 0
|
| 1 | 17 2000 NATURE MEDICINE 6(2):123-125
Burton DR; Parren PWHI
Vaccines and the induction of functional antibodies: Time to look beyond the molecules of natural infection? | 19 | 7
|
| 1 | 18 2000 NATURE MEDICINE 6(2):129-130
Robert-Guroff M
IgG surfaces as an important component in mucosal protection | 15 | 0
|
| 0 | 19 2000 NATURE MEDICINE 6(2):207-210
Mascola JR; Stiegler G; VanCott TC; Katinger H; Carpenter CB; Hanson CE; Beary H; Hayes D; Frankel SS; Birx DL; Lewis MG
Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies | 117 | 117
|
| 1 | 20 2000 NATURE MEDICINE 6(8):929-932
Gerdts V; Babiuk LA; Littel-van den Hurk SV; Griebel PJ
Fetal immunization by a DNA vaccine delivered into the oral cavity | 9 | 1
|
| 1 | 21 2000 NATURE MEDICINE 6(10):1154-1159
Kikuchi T; Worgall S; Singh R; Moore MAS; Crystal RG
Dendritic cells genetically modified to express CD40 ligand and pulsed with antigen can initiate antigen-specific humoral immunity independent of CD4(+) T cells | 13 | 0
|
| 1 | 22 2000 NEW ENGLAND JOURNAL OF MEDICINE 343(17):1263-1265
Nabel GJ; Sullivan NJ
Antibodies and resistance to natural HIV infection. | 3 | 3
|
| 1 | 23 2000 VIROLOGY 270(2):454-463
Dudley KL; Bourne N; Milligan GN
Immune protection against HSV-2 in B-cell-deficient mice | 7 | 0
|
| 1 | 24 2001 ADVANCES IN IMMUNOLOGY, VOL 77 77():195-262
Parren PWHI; Burton DR
The antiviral activity of antibodies in vitro and in vivo | 14 | 6
|
| 2 | 25 2001 ADVANCES IN IMMUNOLOGY, VOL 79 79():1-53
Zinkernagel RM; LaMarre A; Ciurea A; Hunziker L; Ochsenbein AF; McCoy KD; Fehr T; Bachmann MF; Kalinke U; Hengartner H
Neutralizing antiviral antibody responses | 1 | 0
|
| 5 | 26 2001 AIDS 15():S105-S115
Stamatatos L; Davis D
New insights into protective humoral responses and HIV vaccines | 1 | 0
|
| 2 | 27 2001 AIDS RESEARCH AND HUMAN RETROVIRUSES 17(18):1715-1724
Kim YB; Lee MK; Han DP; Cho MW
Development of a safe and rapid neutralization assay using murine leukemia virus pseudotyped with HIV type 1 envelope glycoprotein lacking the cytoplasmic domain | 0 | 0
|
| 3 | 28 2001 AIDS RESEARCH AND HUMAN RETROVIRUSES 17(18):1757-1765
Stiegler G; Kunert R; Purtscher M; Wolbank S; Voglauer R; Steindl F; Katinger H
A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1 | 1 | 0
|
| 1 | 29 2001 AIDS RESEARCH AND HUMAN RETROVIRUSES 17(18):1767-1778
Burkhard MJ; Mathiason CK; Bowdre T; Hoover EA
Feline immunodeficiency virus Gag- and Env-specific immune responses after vaginal versus intravenous infection | 0 | 0
|
| 1 | 30 2001 ANNUAL REVIEW OF BIOCHEMISTRY 70():777-810
Eckert DM; Kim PS
Mechanisms of viral membrane fusion and its inhibition | 21 | 0
|
| 2 | 31 2001 ANNUAL REVIEW OF IMMUNOLOGY 19():253-274
Poignard P; Saphire EO; Parren PWHI; Burton DR
GP120: Biologic aspects of structural features | 8 | 2
|
| 2 | 32 2001 ANTIBODIES IN VIRAL INFECTION 260():145-169
Sullivan NJ
Antibody-mediated enhancement of viral disease | 0 | 0
|
| 1 | 33 2001 ANTIBODIES IN VIRAL INFECTION 260():201-228
Kato H; Kato R; Fujihashi K; McGhee JR
Role of mucosal antibodies in viral infections | 1 | 0
|
| 1 | 34 2001 BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS 285(3):639-643
Patterson LJ; Aberdeen A; Kone J; Haben M; Raymond M; Berkower I
Formation of HIV-1 envelope-hepatitis B core antigen hybrids with high affinity for CD4 | 0 | 0
|
| 2 | 35 2001 CHINESE SCIENCE BULLETIN 46(22):1859-1864
Ding J; He F; Lu Y; Xiao Y; Chen YH
Induction of multi-epitope-specific antibodies against HIV-1 by multi-epitope-vaccines | 0 | 0
|
| 2 | 36 2001 CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY 8(5):859-863
Hemming VG
Use of intravenous immunoglobulins for prophylaxis or treatment of infectious diseases | 0 | 0
|
| 1 | 37 2001 CLINICAL IMMUNOLOGY 101(2):152-157
Anderson DE; Carlos MP; Nguyen L; Torres JV
Overcoming original (antigenic) sin | 0 | 0
|
| 2 | 38 2001 CLINICAL RESEARCH AND REGULATORY AFFAIRS 18(4):293-327
Ensoli B; Cafaro A
Novel strategies toward the development of an effective vaccine to prevent human immunodeficiency virus infection or acquired immunodeficiency virus (Reprinted Aids Clinical Review 2000/2001, pg 23-61, 2001) | 0 | 0
|
| 1 | 39 2001 CRITICAL REVIEWS IN IMMUNOLOGY 21(1-3):103-120
McCluskie MJ; Weeratna RD; Payette PJ; Davis HL
The potential of CpG oligodeoxynucleotides as mucosal adjuvants | 0 | 0
|
| 4 | 40 2001 CURRENT OPINION IN IMMUNOLOGY 13(4):489-495
Mascola JR; Nabel GJ
Vaccines for the prevention of HIV-1 disease | 3 | 0
|
| 2 | 41 2001 CURRENT OPINION IN INFECTIOUS DISEASES 14(4):467-480
Lee LM; Henderson DK
Emerging viral infections | 0 | 0
|
| 1 | 42 2001 EUROPEAN JOURNAL OF BIOCHEMISTRY 268(10):2856-2866
Zeder-Lutz G; Hoebeke J; Van Regenmortel MHV
Differential recognition of epitopes present on monomeric and oligomeric forms of gp160 glycoprotein of human immunodeficiency virus type 1 by human monoclonal antibodies | 1 | 0
|
| 1 | 43 2001 IMMUNOBIOLOGY 204(4):434-441
Tian HJ; Xiao Y; Qin L; Chen YH
Antigenicity and predefined specificities of the multi-epitope vaccine in candidate consisting of neutralizing epitope and mutated epitopes suggested a new way against HIV-1 mutation | 0 | 0
|
| 1 | 44 2001 IMMUNOLOGY LETTERS 75(2):149-152
Dong XN; Xiao Y; Chen YH
ELNKWA-epitope specific antibodies induced by epitope-vaccine recognize ELDKWA- and other two neutralizing-resistant mutated epitopes on HIV-1 gp41 | 1 | 1
|
| 1 | 45 2001 IMMUNOLOGY LETTERS 77(1):3-6
Xiao Y; Lu Y; Chen YH
Epitope-vaccine as a new strategy against HIV-1 mutation | 1 | 0
|
| 1 | 46 2001 IMMUNOLOGY LETTERS 79(1-2):29-36
Broliden K; Hinkula J; Devito C; Kiama P; Kimani J; Trabbatoni D; Bwayo JJ; Clerici M; Plummer F; Kaul R
Functional HIV-1 specific IgA antibodies in HIV-1 exposed, persistently IgG seronegative female sex workers | 0 | 0
|
| 1 | 47 2001 INTERNATIONAL IMMUNOPHARMACOLOGY 1(4):763-768
Tian HJ; Xiao Y; Zhu M; Chen YH
HIV epitope-peptides in aluminum adjuvant induced high levels of epitope-specific antibodies | 1 | 1
|
| 1 | 48 2001 JOURNAL OF HUMAN VIROLOGY 4(2):55-61
Xu WD; Smith-Franklin BA; Li PL; Wood C; He J; Du QJ; Bhat GJ; Kankasa C; Katinger H; Cavacini LA; Posner MR; Burton DR; Chou TC; Ruprecht RM
Potent neutralization of primary human immunodeficiency virus clade C isolates with a synergistic combination of human monoclonal antibodies raised against clade B | 5 | 3
|
| 1 | 49 2001 JOURNAL OF IMMUNOLOGY 166(10):6257-6265
Alfsen A; Iniguez P; Bouguyon E; Bomsel M
Secretory IgA specific for a conserved epitope on gp41 envelope glycoprotein inhibits epithelial transcytosis of HIV-1 | 5 | 0
|
| 1 | 50 2001 JOURNAL OF IMMUNOLOGY 167(12):7180-7191
Hel Z; Tsai WP; Thornton A; Nacsa J; Giuliani L; Tryniszewska E; Poudyal M; Venzon D; Wang XC; Altman J; Watkins DI; Lu WH; von Gegerfelt A; Felber BK; Tartaglia J; Pavlakis GN; Franchini G
Potentiation of simian immunodeficiency virus (SIV)-speciific CD4(+) and CD8(+) T cell responses by a DNA-SIV and NYVAC-SIV prime/boost regimen | 2 | 0
|
| 1 | 51 2001 JOURNAL OF INFECTIOUS DISEASES 183(4):653-656
Pillay K; Coutsoudis A; Agadzi-Naqvi AK; Kuhn L; Coovadia HM; Janoff EN
Secretory leukocyte protease inhibitor in vaginal fluids and perinatal human immunodeficiency virus type 1 transmission | 1 | 0
|
| 1 | 52 2001 JOURNAL OF MEDICAL PRIMATOLOGY 30(4):190-196
Hofmann-Lehmann R; Rasmussen RA; Vlasak J; Smith BA; Baba TW; Liska V; Montefiori DC; McClure HM; Anderson DC; Bernacky BJ; Rizvi TA; Schmidt R; Hill LR; Keeling ME; Katinger H; Stiegler G; Posner MR; Cavacini LA; Chou TC; Ruprecht RM
Passive immunization against oral AIDS virus transmission: An approach to prevent mother-to-infant HIV-1 transmission? | 0 | 0
|
| 1 | 53 2001 JOURNAL OF VIROLOGY 75(2):645-653
Earl PL; Sugiura W; Montefiori DC; Broder CC; Lee SA; Wild C; Lifson J; Moss B
Immunogenicity and protective efficacy of oligomeric human immunodeficiency virus type 1 gp140 | 11 | 5
|
| 2 | 54 2001 JOURNAL OF VIROLOGY 75(5):2224-2234
Cho MW; Kim YB; Lee MK; Gupta KC; Ross W; Plishka R; Buckler-White A; Igarashi T; Theodore T; Byrum R; Kemp C; Montefiori DC; Martin MA
Polyvalent envelope glycoprotein vaccine elicits a broader neutralizing antibody response but is unable to provide sterilizing protection against heterologous Simian/human immunodeficiency virus infection in pigtailed macaques | 11 | 7
|
| 1 | 55 2001 JOURNAL OF VIROLOGY 75(5):2246-2252
Beaumont T; van Nuenen A; Broersen S; Blattner WA; Lukashov VV; Schuitemaker H
Reversal of human immunodeficiency virus type 1 IIIB to a neutralization-resistant phenotype in an accidentally infected laboratory worker with a progressive clinical course | 8 | 3
|
| 1 | 56 2001 JOURNAL OF VIROLOGY 75(9):4165-4175
Letvin NL; Robinson S; Rohne D; Axthelm MK; Fanton JW; Bilska M; Palker TJ; Liao HX; Haynes BF; Montefiori DC
Vaccine-elicited V3 loop-specific antibodies in rhesus monkeys and control of a simian-human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate envelope | 4 | 2
|
| 1 | 57 2001 JOURNAL OF VIROLOGY 75(9):4430-4434
McGettigan JP; Foley HD; Belyakov IM; Berzofsky JA; Pomerantz RJ; Schnell MJ
Rabies virus-based vectors expressing human immunodeficiency virus type 1 (HIV-1) envelope protein induce a strong, cross- reactive cytotoxic T-lymphocyte response against envelope proteins from different HIV-1 isolates | 6 | 0
|
| 1 | 58 2001 JOURNAL OF VIROLOGY 75(11):5370-5374
Hocini H; Becquart P; Bouhlal H; Chomont N; Ancuta P; Kazatchkine MD; Belec L
Active and selective transcytosis of cell-free human immunodeficiency virus through a tight polarized monolayer of human endometrial cells | 2 | 0
|
| 1 | 59 2001 JOURNAL OF VIROLOGY 75(11):5421-5424
Burrer R; Salmon-Ceron D; Richert S; Pancino G; Spiridon G; Haessig S; Roques V; Barre-Sinoussi F; Aubertin AM; Moog C
Immunoglobulin G (IgG) and IgA, but also nonantibody factors, account for in vitro neutralization of human immunodeficiency virus (HIV) type 1 primary isolates by serum and plasma of HIV- infected patients | 2 | 0
|
| 2 | 60 2001 JOURNAL OF VIROLOGY 75(13):5879-5890
Montefiori DC; Safrit JT; Lydy SL; Barry AP; Bilska M; Vo HTT; Klein M; Tartaglia J; Robinson HL; Rovinski B
Induction of neutralizing antibodies and gag-specific cellular immune responses to an R5 primary isolate of human immunodeficiency virus type 1 in rhesus macaques | 2 | 0
|
| 1 | 61 2001 JOURNAL OF VIROLOGY 75(14):6558-6565
Scharf O; Golding H; King LR; Eller N; Frazier D; Golding B; Scott DE
Immunoglobulin G3 from polyclonal human immunodeficiency virus (HIV) immune globulin is more potent than other subclasses in neutralizing HIV type 1 | 2 | 1
|
| 1 | 62 2001 JOURNAL OF VIROLOGY 75(14):6692-6699
Zwick MB; Bonnycastle LLC; Menendez A; Irving MB; Barbas CF; Parren PWHI; Burton DR; Scott JK
Identification and characterization of a peptide that specifically binds the human, broadly neutralizing anti-human immunodeficiency virus type 1 antibody b12 | 3 | 2
|
| 2 | 63 2001 JOURNAL OF VIROLOGY 75(16):7435-7452
Crotty S; Miller CJ; Lohman BL; Neagu MR; Compton L; Lu D; Lu FXS; Fritts L; Lifson JD; Andino R
Protection against simian immunodeficiency virus vaginal challenge by using Sabin poliovirus vectors | 4 | 2
|
| 2 | 64 2001 JOURNAL OF VIROLOGY 75(16):7470-7480
Hofmann-Lehmann R; Vlasak J; Rasmussen RA; Smith BA; Baba TW; Liska V; Ferrantelli F; Montefiori DC; McClure HM; Anderson DC; Bernacky BJ; Rizvi TA; Schmidt R; Hill LR; Keeling ME; Katinger H; Stiegler G; Cavacini LA; Posner MR; Chou TC; Andersen J; Ruprecht RM
Postnatal passive immunization of neonatal macaques with a triple combination of human monoclonal antibodies against oral simian-human immunodeficiency virus challenge | 5 | 0
|
| 4 | 65 2001 JOURNAL OF VIROLOGY 75(17):8340-8347
Parren PWHI; Marx PA; Hessell AJ; Luckay A; Harouse J; Cheng-Mayer C; Moore JP; Burton DR
Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro | 9 | 8
|
| 1 | 66 2001 JOURNAL OF VIROLOGY 75(19):9177-9186
Verrier F; Nadas A; Gorny MK; Zolla-Pazner S
Additive effects characterize the interaction of antibodies involved in neutralization of the primary dualtropic human immunodeficiency virus type 1 isolate 89.6 | 1 | 0
|
| 1 | 67 2001 JOURNAL OF VIROLOGY 75(19):9287-9296
Malenbaum SE; Yang D; Cheng-Mayer C
Evidence for similar recognition of the conserved neutralization epitopes of human immunodeficiency virus type 1 envelope gp120 in humans and macaques | 0 | 0
|
| 2 | 68 2001 JOURNAL OF VIROLOGY 75(21):10200-10207
Montefiori DC; Hill TS; Vo HTT; Walker BD; Rosenberg ES
Neutralizing antibodies associated with viremia control in a subset of individuals after treatment of acute human immunodeficiency virus type 1 infection | 1 | 0
|
| 3 | 69 2001 JOURNAL OF VIROLOGY 75(22):10892-10905
Zwick MB; Labrijn AF; Wang M; Spenlehauer C; Saphire EO; Binley JM; Moore JP; Stiegler G; Katinger H; Burton DR; Parren PWHI
Broadly neutralizing antibodies targeted to the membrane- proximal external region of human immunodeficiency virus type 1 glycoprotein gp41 | 6 | 2
|
| 4 | 70 2001 JOURNAL OF VIROLOGY 75(22):10906-10911
Parker CE; Deterding LJ; Hager-Braun C; Binley JM; Schulke N; Katinger H; Moore JP; Tomer KB
Fine definition of the epitope on the gp41 glycoprotein of human immunodeficiency virus type 1 for the neutralizing monoclonal antibody 2F5 | 3 | 0
|
| 4 | 71 2001 JOURNAL OF VIROLOGY 75(24):12161-12168
Hezareh M; Hessell AJ; Jensen RC; van de Winkel JGJ; Parren PWHI
Effector function activities of a panel of mutants of a broadly neutralizing antibody against human immunodeficiency virus type 1 | 0 | 0
|
| 4 | 72 2001 JOURNAL OF VIROLOGY 75(24):12198-12208
Zwick MB; Wang M; Poignard P; Stiegler G; Katinger H; Burton DR; Parren PWHI
Neutralization synergy of human immunodeficiency virus type 1 primary isolates by cocktails of broadly neutralizing antibodies | 1 | 0
|
| 1 | 73 2001 NATURE 410(6831):1002-1007
Nabel GJ
Challenges and opportunities for development of an AIDS vaccine | 17 | 3
|
| 4 | 74 2001 NATURE MEDICINE 7(11):1225-1231
Chen XN; Scala G; Quinto I; Liu WM; Chun TW; Justement JS; Cohen OJ; vanCott TC; Iwanicki M; Lewis MG; Greenhouse J; Barry T; Venzon D; Fauci AS
Protection of rhesus macaques against disease progression from pathogenic SHIV-89.6PD by vaccination with phage-displayed HIV- 1 epitopes | 2 | 0
|
| 2 | 75 2001 PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 98(11):6342-6347
Marzio G; Verhoef K; Vink M; Berkhout B
In vitro evolution of a highly replicating, doxycycline- dependent HIV for applications in vaccine studies | 6 | 1
|
| 1 | 76 2001 PROTEIN AND PEPTIDE LETTERS 8(5):413-418
Bryson S; Cunningham A; Ho J; Hynes RC; Isenman DE; Barber BH; Kunert R; Katinger H; Klein M; Pai EF
Cross-neutralizing human monoclonal anti-HIV-1 antibody 2F5: Preparation and crystallographic analysis of the free and epitope-complexed forms of its F-ab ' fragment | 0 | 0
|
| 1 | 77 2001 REVIEWS IN MEDICAL VIROLOGY 11(2):117-133
Iijima H; Takahashi I; Kiyono H
Mucosal immune network in the gut for the control of infectious diseases | 0 | 0
|
| 1 | 78 2001 SCANDINAVIAN JOURNAL OF IMMUNOLOGY 53(4):401-409
Decroix N; Hocini H; Quan CP; Bellon B; Kazatchkine MD; Bouvet JP
Induction in mucosa of IgG and IgA antibodies against parenterally administered soluble immunogens | 1 | 0
|
| 1 | 79 2001 TRANSFUSION CLINIQUE ET BIOLOGIQUE 8(4):350-358
Ruprecht RM; Hofmann-Lehmann R; Smith-Franklin BA; Rasmussen RA; Liska V; Vlasak J; Xu W; Baba TW; Chenine AL; Cavacini LA; Posner MR; Katinger H; Stiegler G; Bernacky BJ; Rizvi TA; Schmidt R; Hill LR; Keeling ME; Montefiori DC; McClure HM
Protection of neonatal macaques against experimental SHIV infection by human neutralizing monoclonal antibodies | 0 | 0
|
| 1 | 80 2001 VACCINE 19(20-22):2898-2907
de Haan L; Verweij WR; Holtrop M; Brands R; van Scharrenburg GJM; Palache AM; Agsteribbe E; Wilschut J
Nasal or intramuscular immunization of mice with influenza subunit antigen and the B subunit of Escherichia coli heat- labile toxin induces IgA- or IgG-mediated protective mucosal immunity | 1 | 0
|
| 1 | 81 2001 VACCINE 20(3-4):304-321
Mooij P; Heeney JL
Rational development of prophylactic HIV vaccines based on structural and regulatory proteins | 0 | 0
|
| 1 | 82 2001 VACCINE 20(3-4):563-576
Lee SA; Orque R; Escarpe PA; Peterson ML; Good JW; Zaharias EM; Berman PW; Sheppard HW; Shibata R
Vaccine-induced antibodies to the native, oligomeric envelope glycoproteins of primary HIV-1 isolates | 0 | 0
|
| 1 | 83 2001 VACCINE 20(3-4):594-602
Singh M; Vajdy M; Gardner J; Briones M; O'Hagan D
Mucosal immunization with HIV-1 gag DNA on cationic microparticles prolongs gene expression and enhances local and systemic immunity | 0 | 0
|
| 1 | 84 2001 VIROLOGY 279(2):527-538
Polyanskaya N; Bergmeier LA; Sharpe SA; Cook N; Leech S; Hall G; Dennis M; ten Haaft P; Heeney J; Manca F; Lehner T; Cranage MP
Mucosal exposure to subinfectious doses of SIV primes gut- associated antibody-secreting cells and T cells: Lack of enhancement by nonneutralizing antibody | 1 | 0
|
| 1 | 85 2001 VIROLOGY 280(2):292-300
Spenlehauer C; Gordon CA; Trkola A; Moore JP
A luciferase-reporter gene-expressing T-cell line facilitates neutralization and drug-sensitivity assays that use either R5 or X4 strains of human immunodeficiency virus type 1 | 1 | 1
|
| 1 | 86 2001 VIROLOGY 287(2):436-445
Wu ZG; Jia FL; Mackay G; Kumar A; Narayan O
Antibodies that neutralize SIV(mac)251 in T lymphocytes cause interruption of the viral life cycle in macrophages by preventing nuclear import of viral DNA | 0 | 0
|
| 1 | 87 2001 VIROLOGY 290(1):136-142
Lebigot S; Roingeard P; Thibault G; Lemiale F; Verrier B; Barin F; Brand D
The transmembrane protein of HIV-1 primary isolates modulates cell surface expression of their envelope glycoproteins | 0 | 0
|
| 1 | 88 2002 AIDS 16(2):227-233
Armbruster C; Stiegler GM; Vcelar BA; Jager W; Michael NL; Vetter N; Katinger HWD
A phase I trial with two human monoclonal antibodies (hMAb 2F5, 2G12) against HIV-1 | 1 | 0
|
| 1 | 89 2002 AIDS PATIENT CARE AND STDS 16(5):211-221
Brabin L
Interactions of the female hormonal environment, susceptibility to viral infections, and disease progression | 0 | 0
|
| 1 | 90 2002 AIDS RESEARCH AND HUMAN RETROVIRUSES 18(1):49-56
Nichols CN; Bernal I; Prince AM; Andrus L
Comparison of two different preparations of HIV immune globulin for efficiency of neutralization of HIV type 1 primary isolates | 0 | 0
|
| 6 | 91 2002 ANNUAL REVIEW OF IMMUNOLOGY 20():73-99
Letvin NL; Barouch DH; Montefiori DC
Prospects for vaccine protection against HIV-1 infection and AIDS | 0 | 0
|
| 3 | 92 2002 ANNUAL REVIEW OF MEDICINE 53():149-172
Gandhi RT; Walker BD
Immunologic control of HIV-1 | 1 | 0
|
| 2 | 93 2002 ANNUAL REVIEW OF MEDICINE 53():499-518
Johnson WE; Desrosiers RC
Viral persistence: HIV's strategies of immune system evasion | 2 | 1
|
| 1 | 94 2002 BRITISH MEDICAL JOURNAL 324(7331):237-237
Haigwood NL
Animal studies and HIV research - Animal models for HIV advance and complement clinical studies - Reply | 0 | 0
|
| 1 | 95 2002 DEUTSCHE TIERARZTLICHE WOCHENSCHRIFT 109(3):104-108
Kaup FJ; Schwibbe M
Nonhuman primates as laboratory animals. | 0 | 0
|
| 1 | 96 2002 HYBRIDOMA AND HYBRIDOMICS 21(2):117-122
Chattergoon MA; Maguire HH; Robinson TM; Serrano E; Boyer JD; Weiner DB
Plasmid immunization primes unique DTH responses to HIV-1(MN) envelope epitopes as compared to recombinant protein vaccination | 0 | 0
|
| 2 | 97 2002 IMMUNOLOGIC RESEARCH 25(3):193-200
Xiao Y; Dong XN; Chen YH
Neutralizing antibodies - Mechanism of neutralization and protective activity against HIV-1 | 0 | 0
|
| 9 | 98 2002 JOURNAL OF BIOMEDICAL SCIENCE 9(2):100-111
Smith SM
HIV vaccine development in the nonhuman primate model of AIDS | 0 | 0
|
| 1 | 99 2002 JOURNAL OF CLINICAL INVESTIGATION 109(2):205-211
Khanna KV; Whaley KJ; Zeitlin L; Moench TR; Mehrazar K; Cone RA; Liao ZH; Hildreth JEK; Hoen TE; Shultz L; Markham PB
Vaginal transmission of cell-associated HIV-1 in the mouse is blocked by a topical, membrane-modifying agent | 0 | 0
|
| 2 | 100 2002 JOURNAL OF IMMUNOLOGY 168(4):1877-1885
Gerdts V; Snider M; Brownlie R; Babiuk LA; Griebel PJ
Oral DNA vaccination in utero induces mucosal immunity and immune memory in the neonate | 0 | 0
|
| 2 | 101 2002 JOURNAL OF IMMUNOLOGY 168(8):4001-4011
Sarkar S; Kalia V; Murphey-Corb M; Montelaro RC
Detailed analysis of CD4(+) Th responses to envelope and Gag proteins of simian immunodeficiency virus reveals an exclusion of broadly reactive Th epitopes from the glycosylated regions of envelope | 0 | 0
|
| 1 | 102 2002 JOURNAL OF MEDICAL PRIMATOLOGY 31(1):40-60
Rasmussen RA; Hofmann-Lehmann R; Montefiori DC; Li PL; Liska V; Vlasak J; Baba TW; Schmitz JE; Kuroda MJ; Robinson HL; McClure HM; Lu S; Hu SL; Rizvi TA; Ruprecht RM
DNA prime/protein boost vaccine strategy in neonatal macaques against simian human immunodeficiency virus | 0 | 0
|
| 1 | 103 2002 JOURNAL OF VIROLOGY 76(1):292-302
Pal R; Venzon D; Letvin NL; Santra S; Montefiori DC; Miller NR; Tryniszewska E; Lewis MG; VanCott TC; Hirsch V; Woodward R; Gibson A; Grace M; Dobratz E; Markham PD; Hel Z; Nacsa J; Klein M; Tartaglia J; Franchini G
ALVAC-SIV-gag-pol-env-based vaccination and macaque major histocompatibility complex class I (A*01) delay simian immunodeficiency virus SIVmac-induced immunodeficiency | 3 | 0
|
| 3 | 104 2002 JOURNAL OF VIROLOGY 76(2):517-524
Bradney CP; Sempowski GD; Liao HX; Haynes BF; Staats HF
Cytokines as adjuvants for the induction of anti-human immunodeficiency virus peptide immunoglobulin G (IgG) and IgA antibodies in serum and mucosal secretions after nasal immunization | 0 | 0
|
| 3 | 105 2002 JOURNAL OF VIROLOGY 76(5):2123-2130
Nishimura Y; Igarashi T; Haigwood N; Sadjadpour R; Plishka RJ; Buckler-White A; Shibata R; Martin MA
Determination of a statistically valid neutralization titer in plasma that confers protection against simian-human immunodeficiency virus challenge following passive transfer of high-titered neutralizing antibodies | 0 | 0
|
| 3 | 106 2002 JOURNAL OF VIROLOGY 76(5):2233-2244
Bures R; Morris L; Williamson C; Ramjee G; Deers M; Fiscus SA; Abdool-Karim S; Montefiori DC
Regional clustering of shared neutralization determinants on primary isolates of clade C human immunodeficiency virus type 1 from South Africa | 0 | 0
|
| 2 | 107 2002 JOURNAL OF VIROLOGY 76(6):2835-2847
Srivastava IK; Stamatatos L; Legg H; Kan E; Fong A; Coates SR; Leung L; Wininger M; Donnelly JJ; Ulmer JB; Barnett SW
Purification and characterization of oligomeric envelope glycoprotein from a primary R5 subtype B human immunodeficiency virus | 0 | 0
|
| 2 | 108 2002 JOURNAL OF VIROLOGY 76(7):3309-3317
Fuller DH; Rajakumar PA; Wilson LA; Trichel AM; Fuller JT; Shipley T; Wu MS; Weis K; Rinaldo CR; Haynes JR; Murphey-Corb M
Induction of mucosal protection against primary, heterologous simian immunodeficiency virus by a DNA vaccine | 0 | 0
|
| 1 | 109 2002 JOURNAL OF VIROLOGY 76(7):3511-3521
Grundner C; Mirzabekov T; Sodroski J; Wyatt R
Solid-phase proteoliposomes containing human immunodeficiency virus envelope glycoproteins | 0 | 0
|
| 5 | 110 2002 JOURNAL OF VIROLOGY 76(10):4810-4821
Mascola JR; Louder MK; Winter C; Prabhakara R; De Rosa SC; Douek DC; Hill BJ; Gabuzda D; Roederer M
Human immunodeficiency virus type 1 neutralization measured by flow cytometric quantitation of single-round infection of primary human T cells | 0 | 0
|
| 1 | 111 2002 JOURNAL OF VIROLOGY 76(11):5435-5451
Novitsky V; Smith UR; Gilbert P; McLane MF; Chigwedere P; Williamson C; Ndung'u T; Klein I; Chang SY; Peter T; Thior I; Foley BT; Gaolekwe S; Rybak N; Gaseitsiwe S; Vannberg F; Marlink R; Lee TH; Essex M
Human immunodeficiency virus type 1 subtype C molecular phylogeny: Consensus sequence for an AIDS vaccine design? | 0 | 0
|
| 4 | 112 2002 JOURNAL OF VIROLOGY 76(12):6408-6412
Parren PWHI; Geisbert TW; Maruyama T; Jahrling PB; Burton DR
Pre- and postexposure prophylaxis of Ebola virus infection in an animal model by passive transfer of a neutralizing human antibody | 0 | 0
|
| 1 | 113 2002 SCANDINAVIAN JOURNAL OF IMMUNOLOGY 55(5):458-469
Moreno-Fierros L; Lopez-Revilla R; Resendiz-Albor AA
Differences between the large and small intestine in the immunodominant amoebic proteins recognized by IgG and IgA antibodies in BALB/c mice | 0 | 0
|
| 1 | 114 2002 VACCINE 20(7-8):1169-1180
Ho J; MacDonald KS; Barber BH
Construction of recombinant targeting immunogens incorporating an HIV-1 neutralizing epitope into sites of differing conformational constraint | 0 | 0
|
| 1 | 115 2002 VACCINE 20(11-12):1483-1496
Dunham SP; Flynn JN; Rigby MA; Macdonald J; Bruce J; Cannon C; Golder MC; Hanlon L; Harbour DA; Mackay NA; Spibey N; Jarrett O
Protection against feline immunodeficiency virus using replication defective proviral DNA vaccines with feline interleukin-12 and-18 | 0 | 0
|
| 2 | 116 2002 VACCINE 20(15):1922-1925
Mascola JR
Passive transfer studies to elucidate the role of antibody- mediated protection against HIV-1 | 0 | 0
|
| 1 | 117 2002 VACCINE 20(15):1968-1974
Devico AL; Fouts TR; Shata MT; Kamin-Lewis R; Lewis GK; Hone DM
Development of an oral prime-boost strategy to elicit broadly neutralizing antibodies against HIV-1 | 0 | 0
|
| 1 | 118 2002 VACCINE 20(17-18):2375-2381
Hou YC; Hu WG; Hirano T; Gu XX
A new intra-NALT route elicits mucosal and systemic immunity against Moraxella catarrhalis in a mouse challenge model | 0 | 0
|